COUNCIL ACTIVITIES

Council Members CHAIR Jean Paul Gagnon PhD, RPh, sanofi aventis, USA LEADERSHIP Lieven Annemans PhD, MSc, Mman, Ghent University, Belgium Jon Clouse MS, RPh, United Health Care, USA Michael Drummond PhD, University of York, UK David Eddy PhD, MD, Archimedes, Inc., USA Joel Hay PhD, USC Dept. of Pharmaceutical Economics & Policy, USA Kathleen N. Lohr PhD, MPhil, MA, RTI International, USA Bryan Luce MBA, PhD United BioSource Corporation, USA William McGhan PharmD, PhD, University of the Sciences USA Peter J. Neumann, ScD, Tufts-New England Medical Center, USA Jim Smeeding MBA, RPh, JestaRx Group, USA Sean Sullivan PhD, RPh, MS, University of Washington, USA John E. Ware, Jr. PhD, QualityMetric Inc., USA Milton Weinstein PhD, Harvard School of Public Health, USA

Council Mission The mission of the Health Science Policy Council is to advise the Society on key science research and research policy issues in pharmacoeconomics and outcomes research. The ISPOR Health Science Policy Council, an advisory council to the Board of Directors, was established May 2004 to assure that ISPOR is addressing key research and policy issues in pharmacoeconomics and outcomes research

Council Membership The ISPOR Health Science Policy Council is composed of past ISPOR Presidents, recipients of the Avedis Donabedian Lifetime Achievement Award and key thought leaders selected by the Council.  The Council can invite outcomes research experts to serve on an ad-hoc, as-needed basis.  The Council and the Board of Directors can invite key thought leaders from areas that are under- represented on the Council to assure the Council accurately represents the interests of the ISPOR membership ISPOR members interested in serving on the Council can submit a letter of interest to the Board of Directors

Council Work Plan Council members identify and discuss issues submitted by ISPOR members and Council members during bi-monthly teleconferences and meetings. Issues approved by the Council are then presented to the Board of Directors for discussion and further action.

Issues Currently Under Consideration by HSPC Bridging the Health Measurement Gap Outcomes Research in Evidence-Based Health Care Decision-Making Explaining CEA to Health Care Decision Makers & Their Clients Summary Measures of Population Health IQWiG’s Proposed Drug Cost Benefit Methodology

ISPOR Task Forces Approved by Council and Board of Directors Quality Improvement in Cost Effectiveness Research (QICER) Task Force  Bill McGhan, TF Chair Good Research Practices Task Force on Economic Data Transferability  Mike Drummond, TF Chair Drug Costs Standards Task Force  Jim Smeeding, TF Chair

New Issues ISPOR members are welcome to submit ideas for development and discussion Each issue will be discussed and debated Issue authors will be recognized and informed of issue status Submissions can be made via to the Health Science Policy Council’s ISPOR Staff Liaison at